Risk assessment in fever and neutropenia in children with cancer: What did we learn?

Critical Reviews in Oncology/Hematology

Volumn 72, Issue 1, 2009, Pages 45-55

  te Poele, Esther M ^a   Tissing, Wim J E ^a   Kamps, Willem A ^a   de Bont, Eveline S J M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Antibiotics; Assessment; Cancer; Child; Fever; Neutropenia

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CEFIXIME;

BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEVER; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INFECTION SENSITIVITY; INFECTIOUS COMPLICATION; INNATE IMMUNITY; LABORATORY DIAGNOSIS; LENGTH OF STAY; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; OUTPATIENT CARE; PATIENT CODING; PRACTICE GUIDELINE; PROGNOSIS; RADIODIAGNOSIS; REVIEW; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; CHILD; FEVER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; NEOPLASMS; NEUTROPENIA; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 69349092728     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.12.009     Document Type: Review

References (60)

1. Bodey G.P., Buckley M., Sathe Y.S., and Freireich E.J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64 February (2) (1966) 328-340
2. Klaassen R.J., Goodman T.R., Pham B., and Doyle J.J. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 18 March (5) (2000) 1012-1019
3. Oude Nijhuis C.S., Gietema J.A., Vellenga E., et al. Routine radiography does not have a role in the diagnostic evaluation of ambulatory adult febrile neutropenic cancer patients. Eur J Cancer 39 November (17) (2003) 2495-2498
4. Santolaya M.E., Alvarez A.M., Becker A., et al. Prospective multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer neutropenia and fever. J Clin Oncol 19 July (14) (2001) 3415-3421
5. Santolaya M.E., Alvarez A.M., Aviles C.L., et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer fever and neutropenia. Clin Infect Dis 35 September (6) (2002) 678-683
6. Sickles E.A., Greene W.H., and Wiernik P.H. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 135 May (5) (1975) 715-719
7. Petrilli A.S., Melaragno R., Barros K.V., et al. Fever and neutropenia in children with cancer: a therapeutic approach related to the underlying disease. Pediatr Infect Dis J 12 November (11) (1993) 916-921
8. Oude Nijhuis C., Kamps W.A., Daenen S.M., et al. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 23 October (30) (2005) 7437-7444
9. Ariffin H., Ai C.L., Lee C.L., and Abdullah W.A. Cefepime monotherapy for treatment of febrile neutropenia in children. J Paediatr Child Health 42 December (12) (2006) 781-784
10. Hodgson-Viden H., Grundy P.E., and Robinson J.L. Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr 5 1 (2005) 10
11. Santolaya M.E., Villarroel M., Avendano L.F., and Cofre J. Discontinuation of antimicrobial therapy for febrile neutropenic children with cancer: a prospective study. Clin Infect Dis 25 July (1) (1997) 92-97
12. Mullen C.A., and Buchanan G.R. Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient. J Clin Oncol 8 December (12) (1990) 1998-2004
13. Griffin T.C., and Buchanan G.R. Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: implications for discontinuation of antibiotics and early discharge from the hospital. J Pediatr 121 July (1) (1992) 28-33
14. Lau R.C., Doyle J.J., Freedman M.H., King S.M., and Richardson S.E. Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Pediatr Hematol Oncol 11 July (4) (1994) 417-421
15. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 March (6) (2002) 730-751
16. Paganini H.R., Sarkis C.M., De Martino M.G., et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer 88 June (12) (2000) 2848-2852
17. Shenep J.L., Flynn P.M., Baker D.K., et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis 32 January (1) (2001) 36-43
18. Abbas A.K., Lichtman A.H., and Pober J.S. Innate immunity. In: Abbas (Ed). Cellular and molecular immunology. 4th ed. (2000), W.B. Saunders Company, Philadelphia 270-290
19. Cassatella M.A. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 16 January (1) (1995) 21-26
20. Medzhitov R., and Janeway Jr. C.A. Innate immune recognition and control of adaptive immune responses. Semin Immunol 10 October (5) (1998) 351-353
21. Medzhitov R., and Janeway Jr. C. Innate immunity. N Engl J Med 343 August (5) (2000) 338-344
22. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 February (6) (1999) 448-454
23. Rondinelli P.I., Ribeiro K.D., and de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol 28 October (10) (2006) 665-670
24. Santolaya M.E., Alvarez A.M., Aviles C.L., et al. Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer neutropenia and fever. A prospective multicenter trial. Pediatr Infect Dis J 27 June (6) (2008) 538-543
25. Ammann R.A., Hirt A., Luthy A.R., and Aebi C. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol 41 November (5) (2003) 436-443
26. Lucas K.G., Brown A.E., Armstrong D., Chapman D., and Heller G. The identification of febrile neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 77 February (4) (1996) 791-798
27. Ammann R.A., Hirt A., Luthy A.R., and Aebi C. Predicting bacteremia in children with fever and chemotherapy-induced neutropenia. Pediatr Infect Dis J 23 January (1) (2004) 61-67
28. Paganini H.R., Aguirre C., Puppa G., et al. A prospective multicentric scoring system to predict mortality in febrile neutropenic children with cancer. Cancer 109 June (7) (2007) 2572-2579
29. Alexander S.W., Wade K.C., Hibberd P.L., and Parsons S.K. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 24 January (1) (2002) 38-42
30. Madsen K., Rosenman M., Hui S., and Breitfeld P.P. Value of electronic data for model validation and refinement: bacteremia risk in children with fever and neutropenia. J Pediatr Hematol Oncol 24 May (4) (2002) 256-262
31. Rackoff W.R., Gonin R., Robinson C., Kreissman S.G., and Breitfeld P.B. Predicting the risk of bacteremia in childen with fever and neutropenia. J Clin Oncol 14 March (3) (1996) 919-924
32. Baorto E.P., Aquino V.M., Mullen C.A., Buchanan G.R., and DeBaun M.R. Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer 92 August (4) (2001) 909-913
33. Santolaya M.E., Cofre J., and Beresi V. C-reactive protein: a valuable aid for the management of febrile children with cancer and neutropenia. Clin Infect Dis 18 April (4) (1994) 589-595
34. EL-Maghraby S.M., Moneer M.M., Ismail M.M., Shalaby L.M., and EL-Mahallawy H.A. The diagnostic value of C-reactive protein interleukin-8 and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. J Pediatr Hematol Oncol 29 March (3) (2007) 131-136
35. Kitanovski L., Jazbec J., Hojker S., Gubina M., and Derganc M. Diagnostic accuracy of procalcitonin and interleukin-6 values for predicting bacteremia and clinical sepsis in febrile neutropenic children with cancer. Eur J Clin Microbiol Infect Dis 25 June (6) (2006) 413-415
36. Stryjewski G.R., Nylen E.S., Bell M.J., et al. Interleukin-6 interleukin-8 and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med 6 March (2) (2005) 129-135
37. Hitoglou-Hatzi S., Hatzistilianou M., Gougoustamou D., et al. Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukaemia. Clin Exp Med 5 July (2) (2005) 60-65
38. Soker M., Colpan L., Ece A., Devecioglu C., and Haspolat K. Serum levels of IL-1 beta sIL-2R IL-6 IL-8 and TNF-alpha in febrile children with cancer and neutropenia. Med Oncol 18 1 (2001) 51-57
39. Heney D., Lewis I.J., Evans S.W., Banks R., Bailey C.C., and Whicher J.T. Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis 165 May (5) (1992) 886-890
40. Diepold M., Noellke P., Duffner U., Kontny U., and Berner R. Performance of interleukin-6 and interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk. BMC Infect Dis 8 March (2008) 28
41. Feusner J., Cohen R., O'Leary M., and Beach B. Use of routine chest radiography in the evaluation of fever in neutropenic pediatric oncology patients. J Clin Oncol 6 November (11) (1988) 1699-1702
42. Jones G.R., Konsler G.K., Dunaway R.P., Gold S.H., Cooper H.A., and Wells R.J. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. J Pediatr 124 May (5 Pt 1) (1994) 703-708
43. Bash R.O., Katz J.A., Cash J.V., and Buchanan G.R. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 74 July (1) (1994) 189-196
44. Cohen K.J., Leamer K., Odom L., Greffe B., and Stork L. Cessation of antibiotics regardless of ANC is safe in children with febrile neutropenia. A preliminary prospective trial. J Pediatr Hematol Oncol 17 November (4) (1995) 325-330
45. Wacker P., Halperin D.S., Wyss M., and Humbert J. Early hospital discharge of children with fever and neutropenia: a prospective study. J Pediatr Hematol Oncol 19 May (3) (1997) 208-211
46. Klaassen R.J., Allen U., and Doyle J.J. Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. J Pediatr Hematol Oncol 22 September (5) (2000) 405-411
47. Park J.R., Coughlin J., Hawkins D., Friedman D.L., Burns J.L., and Pendergrass T. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients. Med Pediatr Oncol 40 February (2) (2003) 93-98
48. Ahmed N., El-Mahallawy H.A., Ahmed I.A., Nassif S., El-Beshlawy A., and El-Haddad A. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized prospective study. Pediatr Blood Cancer 49 November (6) (2007) 786-792
49. Aquino V.M., Tkaczewski I., and Buchanan G.R. Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis 25 July (1) (1997) 74-78
50. Paganini H., Rodriguez-Brieshcke T., Zubizarreta P., et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer 91 April (8) (2001) 1563-1567
51. Santolaya M.E., Alvarez A.M., Aviles C.L., et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer fever and neutropenia at low risk for invasive bacterial infection. J Clin Oncol 22 September (18) (2004) 3784-3789
52. Kaplinsky C., Drucker M., Goshen J., Tamary H., Cohen I.J., and Zaizov R. Ambulatory treatment with ceftriaxone in febrile neutropenic children. Isr J Med Sci 30 August (8) (1994) 649-651
53. Mullen C.A., Petropoulos D., Roberts W.M., et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 86 July (1) (1999) 126-134
54. Petrilli A.S., Dantas L.S., Campos M.C., Tanaka C., Ginani V.C., and Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol 34 February (2) (2000) 87-91
55. Aquino V.M., Herrera L., Sandler E.S., and Buchanan G.R. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer 88 April (7) (2000) 1710-1714
56. Paganini H., Gomez S., Ruvinsky S., et al. Outpatient sequential parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center randomized controlled trial in Argentina. Cancer 97 April (7) (2003) 1775-1780
57. Emonts M., Hazelzet J.A., de G.R., and Hermans P.W. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 3 September (9) (2003) 565-577
58. Mockenhaupt F.P., Cramer J.P., Hamann L., et al. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci USA 103 January (1) (2006) 177-182
59. Schlapbach L.J., Aebi C., Otth M., Leibundgut K., Hirt A., and Ammann R.A. Deficiency of mannose-binding lectin-associated serine protease-2 associated with increased risk of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis J 26 November (11) (2007) 989-994
60. Frakking F.N., Van de Wetering M.D., Brouwer N., et al. The role of mannose-binding lectin (MBL) in paediatric oncology patients with febrile neutropenia. Eur J Cancer 42 May (7) (2006) 909-916